Author

Ana García García

Universidad Francisco de VitoriaORCID 0000-0001-7875-4943Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Agustín LahoziD· 1 shared Alberto Mora PerdigueroiD· 1 shared Antonio Giráldez Trujillo· 1 shared Carlos del Pozo-RojasiD· 1 shared Clara Luque‐RiojaiD· 1 shared David Calzón LozanoiD· 1 shared Diego Herráez‐AguilariD· 1 shared Elena de Simone BenitoiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Agustín LahozORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ELOVL6 as a Therapeutic Target: Disrupting c-MYC-Driven Lipid Metabolism to Enhance Chemotherapy in Pancreatic Cancer

Ana García García, María Ferrer Aporta, Germán Vallejo-Palma, Antonio Giráldez Trujillo, Raquel Castillo‐González, David Calzón Lozano, Alberto Mora Perdiguero, Raúl Muñoz Velasco, Miguel Colina Castro, Elena de Simone Benito, Raúl Torres-Ruiz, Sandra Rodríguez, Jonas Dehairs, Johannes V. Swinnen, Juan Carlos García‐Cañaveras, , Victor Javier Sanchez-Arevalo Lobo

This study identifies ELOVL6 as a therapeutic target in pancreatic cancer by showing its role in c-MYC-driven lipid metabolism and its impact on chemotherapy efficacy.

Nature Communications · Feb 16, 2025Peer-reviewedCancer Biology